Production logistics of 177Lu for radionuclide therapy

Applied Radiation and Isotopes

Volumn 59, Issue 2-3, 2003, Pages 109-118

  Pillai, M R A ^a   Chakraborty, Sudipta ^a   Das, Tapas ^a   Venkatesh, Meera ^a   Ramamoorthy, N ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; 177mLu; Radionuclide therapy; Radionuclidic purity; Specific activity; Targeted therapy

Indexed keywords

LOGISTICS; LUTETIUM; NEUTRON IRRADIATION;

PRODUCTION LOGISTICS;

RADIOISOTOPES;

LUTETIUM; LUTETIUM 177; LUTETIUM OXIDE; UNCLASSIFIED DRUG; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BEAM THERAPY; COMPARATIVE STUDY; IRRADIATION; NEUTRON RADIATION; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; RADIOISOTOPE DECAY; RADIOISOTOPE THERAPY; REACTION ANALYSIS; STATISTICS; BONE TUMOR; CHEMISTRY; EVALUATION; HALF LIFE TIME; HUMAN; INSTRUMENTATION; ISOLATION AND PURIFICATION; MATERIALS TESTING; METASTASIS; METHODOLOGY; PALLIATIVE THERAPY; RADIOMETRY; RADIOTHERAPY; SYNTHESIS;

BONE NEOPLASMS; HALF-LIFE; HUMANS; LUTETIUM; MATERIALS TESTING; PALLIATIVE CARE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 0042009841     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(03)00158-1     Document Type: Article

References (38)

1. Atkins H.L., Mausner L.F., Srivastava S.C., Meinken G.E., Cabahug C.J., D'Alessandro T. Sn-117. m (4+) DTPA for palliation of painful osseous metastases a pilot study J. Nucl. Med. 36:1995;725-729.
2. 117mSn(4+) diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 40:2000;2043-2050.
3. 177Lu-labeled polyaminophonates as potential agents for bone pain palliation. Nucl. Med. Commun. 23:2002;67-74.
4. 188Re-Ethylene Dicysteine. a novel agent for possible use in endovascular radiation therapy Nucl. Med. Commun. 21:2000;939-945.
5. 177Lu-labeled cyclic polyaminophonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 57:2002;177-184.
6. 3] octreotide. peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy Nucl. Med. Commun. 19:1998;283-288.
7. Delaloye A.B., Delaloye B. Radiolabeled monoclonal antibodies in tumor imaging and therapy. out of fashion? Eur. J. Nucl. Med. 22:1995;571-580.
8. Deutsch E., Brodack J.W.K., Duetsch F. Radiation Synovectomy revisited. Eur. J. Nucl. Med. 20:1993;1113-1127.
9. Ehrhardt G.J., Ketring A.R., Ayers L.M. Reactor-produced radionuclides at the University of Missouri research reactor. Appl. Radiat. Isot. 49:1998;295-297.
10. Ercan M.T., Caglar M. Therapeutic radiopharmaceuticals. Curr. Pharmaceut. Des. 6:2000;1085-1121.
11. Firestone, R., 1996. In: Shirley, V.S. (Eds.), Table of isotopes, 8th Edition. Wiley, New York.
12. Fritzberg, A.R., Gustavson, L.M., Hylarides, M.D., Reno, J.M., 1995. In: Weiner, D.B., Williams, M.V. (Eds.), Chemical and Stuctural Approaches to Rational Drug Design. CRC Press, Boca Raton, FL, p. 125.
13. 105Rh as a potential radiotherapeutic agent. Appl. Radiat. Isot. 39:1988;257-260.
14. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., Winston D. Skeletal localisation of samarium-153 chelates. potential therapeutic bone agents J. Nucl. Med. 28:1987;495-504.
15. Jhu H., Jain R.K., Baxter L.T. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J. Nucl. Med. 39:1998;65-76.
16. 188Re generator for biomedical applications. Radiochim. Acta. 65:1994;39-46.
17. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl. Med. Biol. 14:1987;223-232.
18. Knapp, F.F., Ambrose, K.R., Beets, A.L., Luo, H., McPherson, D.W., Mirzadeh, S., 1995. Nuclear medicine program progress report for quarter ending September 30, 1995, Oak Ridge National Laboratory, pp. 6-16.
19. 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug. Chem. 12:2001;559-568.
20. Ma D., Ketring A.R., Ehrhardt G.J., Jia W. Production of radiolanthanides and radiotherapy research at MURR. J. Radioanal. Nucl. Chem. Articles. 206:1996;119-126.
21. Mausner L.F., Srivastava S.C. Selection of radionuclides for radioimmunotherapy. Med. Phys. 20:1993;503-509.
22. Mausner L.F., Kolsky K.L., Joshi V., Srivastava S.C. Radionuclide development at BNL for nuclear medicine therapy. Appl. Radiat. Isot. 49:1998;285-294.
23. Meredith R.F., Partridge E.E., Alvarez R.D. Intraperitonial radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37:1996;1491-1496.
24. Mumper R.J., Ryo U.Y., Jay M. Neutron activated holmium-166- Poly (L-Lactic acid) microspheres. a potential agent for internal radiation therapy of hepatic tumours J. Nucl. Med. 32:1992;2139-2143.
25. Neves M., Kling A., Lambrecht R.M. Radionuclide production for therapeutic radiopharmaceuticals. Appl. Radiat. Isot. 57:2002;657-664.
26. 67Zn in a nuclear reactor. Int. J. Appl. Radiat. Isot. 20:1969;121-124.
27. Qaim S.M. Therapeutic radionuclides and nuclear data. Radiochim. Acta. 89:2001;297-302.
28. 153Sm for radionuclide therapy. Nucl. Med. Commun. 23:2002;83-89.
29. Rogers B.E., Anderson C.J., Connett J.M. Comparison of bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes. biodistribution and metabolism Bioconj. Chem. 7:1996;511-522.
30. Sola G.A.R., Arguelles M.G., Bottazzini D.L., Furnari J.C., Parada I.G., Rojo A., Ruiz H.V. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution, and preclinical studies. Radiochim. Acta. 88:2000;157-161.
31. Srivastava S.C., Atkins H.L., Krishnamurthy G.T., Zanzi I., Silberstein E., Meinkein G., Swailem F., Mausner L.F., D'Alessandro T., Cabahug C.J., Lau Y., Park T., Madajewicz S. Treatment of metastatic bone pain with tin 117. m stannic DTPA a phase I/II clinical study Clin. Cancer Res. 4:1998;61-68.
32. Srivastava S.C., Dadachova E. Recent advances in radionuclide therapy. Semin. Nucl. Med. 31:2001;330-341.
33. 131I J. Nucl. Med. 42:2001;967-974.
34. Unni P.R., Pillai M.R.A. Preparation and radiochemical separation of Rh-105 for radiopharmaceutical applications. Radiochim. Acta. 90:2002;363-369.
35. 90Y generator. Radiochim Acta. 89:2001;413-417.
36. Volkert W.A., Hoffman T.J. Therapeutic radiophamaceuticals. Chem. Rev. 99:1999;2269-2292.
37. Volkert W.A., Goeckeler W.F., Ehrhardt G.J., Ketring A.R. Therapeutic radionuclides. production and decay property considerations J. Nucl. Med. 32:1991;174-185.
38. Wessels B.W., Rogus R.D. Radionuclide selection and model absorbed dose calculations for radiolabelled tumor associated antibodies. Med. Phys. 11:1984;638-645.